Stock Track | Viatris Plunges 7.21% Pre-Market on Disappointing Q4 Earnings

Stock Track
02-27

Viatris Inc. (VTRS) stock plummeted 7.21% in pre-market trading on Thursday, following the company's release of disappointing fourth-quarter 2024 financial results.

The pharmaceutical giant reported adjusted earnings per share of $0.54, missing analysts' consensus estimate of $0.57 by 5.26%. Additionally, Viatris' quarterly revenue of $3.52 billion fell short of the expected $3.61 billion, marking an 8.13% year-over-year decline.

As a global healthcare company focused on providing access to high-quality medicines worldwide, Viatris' ability to meet or exceed earnings expectations is crucial for investor confidence. The missed targets on both earnings and revenue suggest challenges in executing the company's growth strategy, which likely weighed heavily on the stock's performance in early trading.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10